Skip to main content
. 2019 Feb 28;82(3):227–233. doi: 10.4046/trd.2018.0070

Figure 3. Relationship between programmed death-ligand 1 (PD-L1) immunohistochemical 22C3 pharmDx and SP263 assay. (A) Scatter diagrams illustrating the relationship between expression levels with respect to 22C3 pharmDx and SP263 assays. Each point in the diagram indicates the percentage of positive tumor cells in the 22C3 (x-axis) and SP263 (y-axis) assays. A significantly high relationship was observed between the 22C3 and SP263 assays (r=0.826; 95% confidence interval, 0.736-0.916). (B) Analytic comparison of the percentage of tumor proportion score by case for each assay. Data points expressed the scores on each case (blue points for 22C3 pharmDx and red points for SP263 assay).

Figure 3